Corbus制药控股 CRBP 深 沪
等待开盘 03-26 09:30:00 美东时间
8.13
-0.050
-0.61%
华盛通- 最 高8.595
- 今 开8.30
- 成交量 15.96万股
- 最 低 8.10
- 昨 收 8.18
- 总市值 1.44亿
- 52周最高 20.56
- 市盈率 静 --
- 换手率 0.90%
- 52周最低 4.64
- 委 比 91.61%
- 总股本 1773.65万
- 历史最高 323.40
- 量 比 1.46
- 振 幅 6.05%
- 历史最低 3.00
- 每 手 1
- 风险率 2.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Corbus Pharmaceuticals' CEO, Yuval Cohen, will participate in the BMO 2026 Metabolic Health Summit on March 24. Corbus is developing CRB-913, an oral CB1 inverse agonist for obesity, showing promising results in Phase 1 studies. The company expects to complete Phase 1b trials in summer 2026. The summit will discuss metabolic disease treatments, with networking opportunities. Corbus focuses on innovative therapies for obesity and oncology.
03-18 12:00
美股机会日报 | 伊朗国家媒体：英伟达、谷歌等美国巨头或成打击目标！美国2月通胀数据将于20:30公布
伊朗国家媒体：英伟达、谷歌等美国巨头或成打击目标！美国2月通胀数据将于20:30公布，市场预计趋于平稳；甲骨文盘前涨超9%，上季业绩大超预期>>
03-11 20:16
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $57
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $53 to $57.
03-10 22:14
Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Corbus Pharmaceuticals (NASDAQ:CRBP) announced its Q4 earnings on Monday, March...
03-09 19:46
Corbus Pharmaceuticals Q4 net loss widens on higher clinical development costs
Corbus Pharmaceuticals Q4 net loss widens on higher clinical development costs Overview Clinical stage pharma's Q4 net loss widened to $20.6 mln Operating expenses for Q4 rose to $22 mln, driven by clinical development costs Outlook Corbus completed $75 mln public offering, extending cash runway int
03-09 19:40
Corbus Pharmaceuticals Q4 EPS $(1.25) Beats $(1.38) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.38) by 9.42 percent. This is a 60.26 percent decrease over losses of $(0.78) per share
03-09 19:33
Corbus Pharmaceuticals Q4 net loss rises 116% to USD 20.56 million
Corbus Pharmaceuticals Q4 net loss rises 116% to USD 20.56 million Corbus reported a Q4 net loss of USD 20.56 million, up 116% year over year, with net loss per share of USD 1.25. Operating expenses in Q4 rose 74% to USD 21.97 million, driven by higher clinical development spending. For FY 2025, the
03-09 19:30
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Holdings provided updates and financial results for Q4 and 2025, highlighting promising efficacy for CRB-701 in head and neck and cervical cancers, and weight loss with CRB-913 for obesity. CRB-701 showed high response rates with favorable safety, and CRB-913 demonstrated rapid weight loss. The company completed a $75M public offering, extending cash runway to 2028. Financial data showed a net loss of $20.6M for Q4 and $78....
03-09 11:30
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook
Corbus Pharmaceuticals ( ($CRBP) ) has shared an update. Corbus Pharmaceuticals...
02-25 21:18
